SP Group (SPG) Q2 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2026 earnings summary
25 Aug, 2026Executive summary
Achieved record revenue and earnings in H1 2026, with revenue up 32.9% year-over-year to DKK 1,950 million and EBITDA up 36.2% to DKK 397 million, driven by both organic growth and acquisitions.
Expanded global footprint to 14 countries with the acquisition of OGM Moulding Ltd. in the UK and production expansion in Poland.
Upgraded full-year 2026 guidance twice, now expecting 24%-30% revenue growth with stable margins, following robust H1 results.
Strong performance across all product groups, with Healthcare, Cleantech, and Foodtech showing notable growth.
Significant growth in both own products and sub-supplier projects, supported by organic expansion and acquisitions.
Financial highlights
Q2 2026 revenue grew 44.6% year-over-year to DKK 984 million; H1 2026 revenue reached DKK 1,950 million, up 32.9% year-over-year, with organic growth at 19.7%.
EBITDA margin for H1 2026 was 20.3%, up from the prior year; EBIT increased 45.4% to DKK 280 million; EBT margin was 12.7%.
Profit before tax rose 50.3% to DKK 248 million; earnings per share (diluted) increased 55.1% to DKK 16.49.
Cash flow from operations improved to DKK 291 million in H1 2026; equity increased by DKK 91 million to DKK 1,900 million.
Net interest-bearing debt reduced by DKK 119 million in H1 2026, now at DKK 1,341 million.
Outlook and guidance
Full-year 2026 revenue expected at DKK 3.6–3.8 billion, reflecting 24%-30% growth, with EBITDA margin at 19%-21% and EBT margin at 11%-13%.
Growth driven by both organic expansion and acquisitions, with 16%-17% of growth from acquisitions.
High activity levels and capacity utilization expected to continue, despite ongoing geopolitical and supply chain challenges.
Cautious approach to guidance due to geopolitical tensions and potential stockpiling effects.
Latest events from SP Group
- Record H1 2026 growth and UK expansion led to upgraded outlook and strong margins.SPG
Q2 2026 - Record Q1 2026 growth, robust outlook, and active capital returns amid global uncertainty.SPG
Q1 2026 - Record Q1 2026 revenue and profit growth, outlook and guidance remain robust.SPG
Q1 2026 - Record Q4 and strong 2026 growth outlook, boosted by Idé-Pro acquisition.SPG
Q4 2025 - Record Q4 and Idé-Pro acquisition set stage for strong 2026 growth amid ongoing uncertainties.SPG
Q4 2025 - H1 2025 saw lower revenue and earnings, but margin guidance and growth projects remain on track.SPG
Q2 2025 - Strong H1 2024 growth, upgraded outlook, and international expansion led by healthcare sales.SPG
Q2 2024 - Q1 2025 delivered 8.8% revenue growth and margin expansion, with outlook unchanged.SPG
Q1 2025 - Record revenue and margin growth in 2024; cautious 2025 outlook with focus on own products.SPG
Q4 2024